Is Egrifta (Tesamorelin) Legal in Virginia? How to Access It Legally
HealthRX.com
Egrifta is federally legal with a valid prescription
See the public record for Tesamorelin
At a glance
- Federal status / FDA-approved prescription drug; application BLA 022505 first approved November 10, 2010 [1]
- Approved use / Excess abdominal fat in HIV-infected adults with lipodystrophy [2]
- Current products / Egrifta SV 2 mg vial and Egrifta WR 11.6 mg vial, labels dated July 29, 2026 [2][3]
- Daily dose / 1.4 mg for Egrifta SV, 1.28 mg for Egrifta WR; injected into the abdomen; not substitutable [2][3]
- Not approved for / Weight loss, general fat loss, anti-aging or muscle building [2]
Is tesamorelin legal in the United States?
Yes, as a prescription drug. Egrifta (tesamorelin acetate) was first approved on November 10, 2010 under application BLA 022505, and the current labels are Egrifta SV (2 mg vial) and Egrifta WR (11.6 mg vial), both dated July 29, 2026 [1][2][3].
The only approved indication is reduction of excess abdominal fat in HIV-infected adults with lipodystrophy [2]. The same label section states that long-term cardiovascular safety has not been established, that the drug is not indicated for weight loss management because its effect on weight is neutral, and that no data show it improves adherence to antiretroviral therapy [2]. Use in people without HIV lipodystrophy falls outside the approved indication [2].
Prescription status
Egrifta is listed in Drugs@FDA as a prescription product, approved for that single indication [1][2]. This page covers the drug's federal approval status and labeled use. It does not cover Virginia's prescribing, pharmacy or telemedicine requirements.
Questions worth asking
What about compounded tesamorelin?
Tesamorelin does not appear on FDA's page of bulk substances that may raise significant safety risks when compounded (content dated 04/22/2026). It also appears in no category of FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026) or of its list for outsourcing facilities (updated March 21, 2025). So FDA has made no category-based statement about compounding tesamorelin [4][5][6]. It is already a component of an FDA-approved drug, Egrifta [1][2].
Tesamorelin is also not one of the six peptides named in HHS's draft enforcement-discretion policy for compounding (BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500), filed October 28, 2026 as Federal Register document 2026-22192 [7][8].
Compounded drugs are not FDA-approved: FDA does not review their safety, effectiveness or quality before they are marketed [8].
What the label says about safety and monitoring
Egrifta is contraindicated in people with disruption of the hypothalamic-pituitary axis (hypophysectomy, hypopituitarism, pituitary tumor or surgery, head irradiation or head trauma), active malignancy, known hypersensitivity to tesamorelin or its excipients, and pregnancy [2][3]. In pregnancy, rat studies at roughly two to four times the human exposure produced hydrocephalus in offspring, and the label says to discontinue if pregnancy occurs [2].
Glucose is the main laboratory issue. Tesamorelin can cause glucose intolerance: by week 26, 5% of treated patients had an HbA1c of 6.5% or higher versus 1% on placebo, a hazard ratio of about 3.3 (95% CI 1.4 to 9.6). The label directs prescribers to evaluate glucose before starting and to monitor during therapy [2]. IGF-1 rises too: among patients treated for 26 weeks, 47% had IGF-1 above 2 SDS and 36% above 3 SDS; among those treated for 52 weeks, 34% and 23% [2]. The label asks prescribers to monitor IGF-1 and consider discontinuing if levels stay high (for example above 3 SDS), particularly when the fat-loss response is not robust [2].
Fluid retention (edema, joint pain, carpal tunnel syndrome) and hypersensitivity reactions are labeled warnings. Hypersensitivity reactions occurred in 4% of patients in trials, and the label advises seeking prompt medical attention and discontinuing treatment if one is suspected [2]. Injection-site reactions occurred in 25% of tesamorelin-treated patients versus 14% on placebo during the first 26 weeks [2].
Which product the prescription is for
Egrifta SV is 1.4 mg (0.35 mL of the reconstituted solution) injected into the abdomen once daily, reconstituted only with the supplied Sterile Water for Injection and given immediately [2]. Egrifta WR is 1.28 mg (0.16 mL) once daily, reconstituted with 1.3 mL of Bacteriostatic Water for Injection, with one vial supplying seven daily doses [3]. The labels state the two are not substitutable [3].
Frequently asked questions
Is Egrifta (tesamorelin) legal in Virginia?
Is tesamorelin approved for weight loss or anti-aging?
Who should not use Egrifta?
What is the Egrifta SV dose?
Does tesamorelin raise blood sugar?
References
Show all 8 referencesHide references
- Drugs@FDA: FDA-Approved Drugs.
- U.S. National Library of Medicine, DailyMed. Egrifta SV (tesamorelin) for injection, 2 mg vial prescribing information. Egrifta SV (tesamorelin) for injection, 2 mg vial label
- U.S. National Library of Medicine, DailyMed. Egrifta WR (tesamorelin) for injection, 11.6 mg vial prescribing information. Egrifta WR (tesamorelin) for injection, 11.6 mg vial label
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Official web page.
- Official web page.